UA117490C2 - Сполуки ізоіндоліну або ізохіноліну, спосіб їх одержання і фармацевтичні композиції, що їх містять - Google Patents

Сполуки ізоіндоліну або ізохіноліну, спосіб їх одержання і фармацевтичні композиції, що їх містять

Info

Publication number
UA117490C2
UA117490C2 UAA201601395A UAA201601395A UA117490C2 UA 117490 C2 UA117490 C2 UA 117490C2 UA A201601395 A UAA201601395 A UA A201601395A UA A201601395 A UAA201601395 A UA A201601395A UA 117490 C2 UA117490 C2 UA 117490C2
Authority
UA
Ukraine
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
isoquinoline compounds
new isoindoline
Prior art date
Application number
UAA201601395A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джеймс Едвард Пол Девідсон
Джеймс Брук Маррей
Ай-Джен Чен
Клер Уолмслі
Марк Додсворт
Йоханнес В. Г. Майснер
Пол Бро
Імре Фейеш
Янош Татаі
Міклош Ньєргеш
Андраш Котші
Золтан Славік
Олівьє Генесте
Тіран Арнод Лє
Дігуарер Тьєррі Лє
Жан-Мішель Анлан
Жером-Бенуа Старк
Анн-Франсуаз Гійузік
Нантей Гійом де
Original Assignee
Ле Лаборатуар Сервьє
Верналіс (Ар Енд Ді) Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервьє, Верналіс (Ар Енд Ді) Лімітед filed Critical Ле Лаборатуар Сервьє
Publication of UA117490C2 publication Critical patent/UA117490C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
UAA201601395A 2013-07-23 2014-07-22 Сполуки ізоіндоліну або ізохіноліну, спосіб їх одержання і фармацевтичні композиції, що їх містять UA117490C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1357276A FR3008977A1 (fr) 2013-07-23 2013-07-23 Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2014/065764 WO2015011164A1 (en) 2013-07-23 2014-07-22 New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
UA117490C2 true UA117490C2 (uk) 2018-08-10

Family

ID=49911606

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201601395A UA117490C2 (uk) 2013-07-23 2014-07-22 Сполуки ізоіндоліну або ізохіноліну, спосіб їх одержання і фармацевтичні композиції, що їх містять

Country Status (49)

Country Link
US (3) US9809574B2 (enExample)
EP (1) EP3024826B1 (enExample)
JP (1) JP6395829B2 (enExample)
KR (1) KR102008431B1 (enExample)
CN (2) CN109456324B (enExample)
AP (1) AP2016008989A0 (enExample)
AR (1) AR097009A1 (enExample)
AU (1) AU2014295101B2 (enExample)
BR (1) BR112016001080B1 (enExample)
CA (1) CA2919572C (enExample)
CL (1) CL2016000148A1 (enExample)
CR (1) CR20160030A (enExample)
CU (1) CU24352B1 (enExample)
CY (1) CY1121247T1 (enExample)
DK (1) DK3024826T3 (enExample)
DO (1) DOP2016000009A (enExample)
EA (1) EA032301B1 (enExample)
ES (1) ES2711371T3 (enExample)
FR (1) FR3008977A1 (enExample)
GE (2) GEP20207070B (enExample)
HK (1) HK1218754A1 (enExample)
HR (1) HRP20190277T1 (enExample)
HU (1) HUE041443T2 (enExample)
IL (1) IL243449A0 (enExample)
JO (1) JO3457B1 (enExample)
LT (1) LT3024826T (enExample)
MA (1) MA38801B1 (enExample)
MD (1) MD4793C1 (enExample)
ME (1) ME03346B (enExample)
MX (1) MX365373B (enExample)
MY (1) MY193619A (enExample)
NI (1) NI201600016A (enExample)
NZ (1) NZ716155A (enExample)
PE (1) PE20160241A1 (enExample)
PH (1) PH12016500034B1 (enExample)
PL (1) PL3024826T3 (enExample)
PT (1) PT3024826T (enExample)
RS (1) RS58344B1 (enExample)
RU (1) RU2689305C2 (enExample)
SA (1) SA516370439B1 (enExample)
SG (1) SG11201600205XA (enExample)
SI (1) SI3024826T1 (enExample)
TN (1) TN2016000003A1 (enExample)
TR (1) TR201819155T4 (enExample)
TW (1) TWI560184B (enExample)
UA (1) UA117490C2 (enExample)
UY (1) UY35664A (enExample)
WO (1) WO2015011164A1 (enExample)
ZA (1) ZA201600198B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA037300B1 (ru) 2016-04-20 2021-03-05 Бристол-Маерс Сквибб Компани Замещенные бициклические гетероциклические соединения
MX2020014082A (es) 2018-06-27 2021-04-13 Proteostasis Therapeutics Inc Compuestos que mejoran la actividad del proteasoma.
CN114728926A (zh) * 2019-11-15 2022-07-08 武汉朗来科技发展有限公司 一种rock抑制剂及其制备方法和用途
CN112010796B (zh) * 2020-09-17 2022-04-22 浙江大学 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法
CN116917009A (zh) 2021-02-19 2023-10-20 美国迈胜医疗系统有限公司 用于粒子治疗系统的机架
EP4313964A1 (en) * 2021-03-24 2024-02-07 Les Laboratoires Servier New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h )-carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds
US20250179047A1 (en) 2022-02-24 2025-06-05 Les Laboratoires Servier 5-[7-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-1,2,3,4 tetrahydroisoquinolin-6-yl]-1h-pyrrole-3-carboxamide derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
CN121001985A (zh) * 2023-03-31 2025-11-21 三井化学株式会社 氨基甲酸酯化合物
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス, インク. プロテインキナーゼモジュレーターおよびその使用方法
WO2004096774A1 (en) * 2003-05-01 2004-11-11 Glaxo Group Limited Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
CA2577752A1 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
EP1778206A4 (en) * 2004-08-20 2009-08-05 Univ Michigan SMALL MOLECULE INHIBITORS FROM MEMBERS OF THE ANTIOPTOTIC BCL-2 FAMILY AND USES THEREOF
BRPI0607545A2 (pt) * 2005-02-15 2016-11-01 Novo Nordisk As composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
CA2682356C (en) 2007-04-16 2016-06-14 Abbott Laboratories 7-substituted indole mcl-1 inhibitors
WO2009073545A2 (en) 2007-11-30 2009-06-11 Maxthera, Inc. Tetrahydro-isoquinoline ppat inhibitors as antibacterial agents
EP2252617A1 (en) 2008-02-13 2010-11-24 CGI Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof
US7984530B2 (en) 2008-02-14 2011-07-26 Tory Reynolds Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same
US9346795B2 (en) * 2011-05-25 2016-05-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic Bcl inhibitors
BR112014015322A8 (pt) * 2011-12-23 2017-06-13 Novartis Ag compostos e composições para inibir a interação de bcl2 com parceiros de ligação
US10228738B2 (en) 2011-12-27 2019-03-12 Intel Corporation Methods and systems to control power gates during an active state of a gated domain based on load conditions of the gated domain
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PL3024826T3 (pl) 2019-05-31
BR112016001080B1 (pt) 2022-04-05
CA2919572C (en) 2017-06-20
TR201819155T4 (tr) 2019-01-21
CL2016000148A1 (es) 2016-08-12
NZ716155A (en) 2019-05-31
JP2016525529A (ja) 2016-08-25
US20180002313A1 (en) 2018-01-04
US20200262816A1 (en) 2020-08-20
RS58344B1 (sr) 2019-03-29
SI3024826T1 (sl) 2019-03-29
CU20160010A7 (es) 2016-06-29
HK1222856A1 (en) 2017-07-14
PH12016500034A1 (en) 2016-03-28
US10689364B2 (en) 2020-06-23
GEAP201914063A (en) 2019-10-25
AR097009A1 (es) 2016-02-10
CA2919572A1 (en) 2015-01-29
DOP2016000009A (es) 2016-03-15
KR20160033224A (ko) 2016-03-25
CN109456324B (zh) 2022-04-22
ZA201600198B (en) 2019-07-31
PH12016500034B1 (en) 2016-03-28
ES2711371T3 (es) 2019-05-03
JP6395829B2 (ja) 2018-09-26
CN109456324A (zh) 2019-03-12
NI201600016A (es) 2016-02-11
RU2689305C2 (ru) 2019-05-27
MX2016000904A (es) 2016-04-25
MX365373B (es) 2019-05-31
HUE041443T2 (hu) 2019-05-28
GEP20207070B (en) 2020-02-25
EA032301B1 (ru) 2019-05-31
IL243449A0 (en) 2016-02-29
CR20160030A (es) 2016-03-09
EP3024826A1 (en) 2016-06-01
MD4793C1 (ro) 2022-09-30
HRP20190277T1 (hr) 2019-04-05
SG11201600205XA (en) 2016-02-26
MA38801A1 (fr) 2018-05-31
ME03346B (me) 2019-10-20
MA38801B1 (fr) 2019-03-29
CU24352B1 (es) 2018-07-05
MD4793B1 (ro) 2022-02-28
UY35664A (es) 2015-01-30
LT3024826T (lt) 2019-02-25
TN2016000003A1 (en) 2017-07-05
CN105431422A (zh) 2016-03-23
AU2014295101B2 (en) 2018-05-31
BR112016001080A2 (enExample) 2017-07-25
AP2016008989A0 (en) 2016-01-31
US9809574B2 (en) 2017-11-07
CY1121247T1 (el) 2020-05-29
DK3024826T3 (en) 2019-03-04
HK1218754A1 (zh) 2017-03-10
PE20160241A1 (es) 2016-04-30
EA201600122A1 (ru) 2016-07-29
US20160194304A1 (en) 2016-07-07
FR3008977A1 (fr) 2015-01-30
AU2014295101A1 (en) 2016-02-04
WO2015011164A1 (en) 2015-01-29
JO3457B1 (ar) 2020-07-05
PT3024826T (pt) 2019-01-28
CN105431422B (zh) 2019-08-30
KR102008431B1 (ko) 2019-08-07
US11028070B2 (en) 2021-06-08
SA516370439B1 (ar) 2019-06-27
TW201504228A (zh) 2015-02-01
MD20160018A2 (ro) 2016-07-31
TWI560184B (en) 2016-12-01
MY193619A (en) 2022-10-20
RU2016106003A (ru) 2017-08-28
EP3024826B1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
UA117490C2 (uk) Сполуки ізоіндоліну або ізохіноліну, спосіб їх одержання і фармацевтичні композиції, що їх містять
PH12014000179A1 (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
JO3195B1 (ar) مشتقات أندوليزين جديدة, وطريقة تحضيرهم والتركيبات الصيدلانية التي تحتوي عليهم لعلاج السرطان
MX351581B (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
JO3160B1 (ar) مشتقات الفوسفات الجديدة, طريقة تحضيرها والتركيبات الدوائية التي تحتوي عليها
JO3807B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
JO3675B1 (ar) مشتقات هيدروكسي إستر جديدة،عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
PH12017502266A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
PH12016500057A1 (en) Novel indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
MX364479B (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX2015016400A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
MX368759B (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.